Clearmind Medicine Inc. Form 6-K Summary
Business Context and Reporting Period
Clearmind Medicine Inc., a foreign private issuer, filed this Form 6-K for the month of April 2026. The filing reports on a specific financing transaction executed on April 20, 2026, involving the issuance of convertible promissory notes.
Key Financial Metrics
The filing details a specific capital raise transaction rather than providing comprehensive financial statements for a reporting period.
- Transaction Date: April 20, 2026
- Instrument: Convertible Promissory Notes
- Principal Amount Issued: $2,700,000
- Purchase Price (Cash Proceeds): $2,430,000 (90% of principal)
- Investors: CLA Investors (previously engaged under September 2025 agreements)
- Expected Closing Date: On or about April 21, 2026
The filing does not provide data on revenue, profit, operating cash flow, margins, total debt, or liquidity positions outside of this specific transaction.
Material Changes
This transaction represents a drawdown under the securities purchase agreements (SPAs) entered into on September 17, 2025, which authorized the issuance of up to $10,000,000 in aggregate principal amount of convertible promissory notes. The current issuance of $2,700,000 reduces the remaining capacity under the original SPA.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the agreement and the expected closing date. The filing does not contain specific forward-looking guidance, risk factors, or discussion of contingencies beyond the terms of the note issuance. The transaction is being incorporated by reference into the Company's Registration Statements on Form F-3 and Form S-8.
Key Facts for Investor Verification
- Verify the final closing date and receipt of the $2,430,000 cash proceeds.
- Review the specific terms of the convertible promissory notes (interest rate, conversion price, maturity date) which are not detailed in this summary filing.
- Confirm the remaining principal capacity available under the September 2025 SPAs ($7,300,000).
- Check subsequent filings for the impact of this debt on the Company's overall capital structure and dilution upon conversion.